Găman Mihaela, Vlădăreanu Ana-Maria, Radesi Sînziana
Department of Hematology, Emergency Universitary Hospital, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Rom J Intern Med. 2011;49(1):25-30.
Myeloid disorders constitute a subgroup of hematological malignancies of myeloid lineage. In the revised 2008 WHO classification system, the nomenclature for myeloproliferative entities has been changed from "chronic myeloproliferative diseases" to "myeloproliferative neoplasms", the definition criteria has changed, and and the MDS/MPN has emerged as a well defined entity the subgroup formerly known as "myelodysplastic/myeloproliferative diseases" has changed to "myelodysplastic/myeloproliferative neoplasms". The World Health Organization classification of myeloid neoplasms relies on the association of clinical, morphologic, immunophenotypic and genetic diagnostic features. The current review highlights these changes and also provides diagnostic algorithms that are tailored to routine clinical practice.
髓系疾病构成了髓系血统的血液系统恶性肿瘤的一个亚组。在2008年世界卫生组织（WHO）修订的分类系统中，髓系增殖性疾病的命名已从“慢性髓系增殖性疾病”改为“髓系增殖性肿瘤”，定义标准发生了变化，骨髓增生异常综合征/骨髓增殖性肿瘤（MDS/MPN）已成为一个明确的实体，以前称为“骨髓增生异常/髓系增殖性疾病”的亚组已改为“骨髓增生异常/髓系增殖性肿瘤”。世界卫生组织对髓系肿瘤的分类依赖于临床、形态学、免疫表型和基因诊断特征的关联。本综述强调了这些变化，并提供了针对常规临床实践的诊断算法。
